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Abstract
 
Reduced levels of wild-type mannose-binding lectin (MBL) may increase susceptibility for
infection, other common diseases, and death. We investigated associations between MBL
deficiency and risk of infection, other common diseases, and death during 24, 24, and 8 yr of
follow-up, respectively. We genotyped 9,245 individuals from the adult Danish population
for three MBL deficiency alleles, 
 
B
 
, 
 
C
 
, and 
 
D
 
, as opposed to the normal noncarrier 
 
A
 
 allele.
Hospitalization incidence per 10,000 person 
 
  
 
yr was 644 in noncarriers compared with 631
in heterozygotes (log-rank: P 
 
  
 
0.39) and 658 in deficiency homozygotes (P 
 
  
 
0.53). Death
incidence per 10,000 person 
 
  
 
yr was 235 in noncarriers compared with 244 in heterozygotes
(P 
 
  
 
0.44) and 274 in deficiency homozygotes (P 
 
  
 
0.12). After stratification by specific cause
of hospitalization or death, only hospitalization from cardiovascular disorders was increased in
deficiency homozygotes versus noncarriers (P 
 
  
 
0.02). When retested in two case control
studies, this association could not be confirmed. Incidence of hospitalization or death from
infections or other serious common disorders did not differ between deficiency homozygotes
and noncarriers. In conclusion, in this large study in an ethnically homogenous Caucasian
population, there was no evidence for significant differences in infectious disease or mortality
in MBL-deficient individuals versus controls. Our results suggest that MBL deficiency is not
a major risk factor for morbidity or death in the adult Caucasian population.
Key words: complement • mannan • innate immunity • infection • genetics
 
Introduction
 
Infectious diseases are important causes of morbidity and
mortality worldwide (1, 2). Our first set of immune re-
sponses during infection constitutes the innate immune
system. A central player in this system is mannose-binding
lectin (MBL), an acute phase protein with the capacity to
bind to a broad range of bacteria and vira and subsequently
kill them by activating the complement system (3–5).
About 5% of Caucasians have an inherited deficiency of
MBL leading to reduced plasma levels of wild-type MBL
protein (5–7). This may impair normal innate immune
function and increase susceptibility for infection (8). Because
MBL may also play an important role in other serious com-
mon diseases like atherosclerosis (9, 10), chronic pulmonary
disease (11, 12), and cancer (13, 14), MBL deficiency could
also affect risk of these diseases and mortality.
MBL deficiency is associated with homozygosity for
either of the three deficiency alleles of the MBL gene,
the 
 
B
 
, 
 
C
 
, and 
 
D
 
 alleles (5–7). These mutant alleles are also
designated 
 
O
 
 alleles as opposed to the normal noncarrier
 
A
 
 allele. In previous studies, MBL deficiency has been
associated with increased susceptibility for bacterial and viral
infections (8), as well as with many other diseases like
atherosclerosis (9, 10), leukemia (14), and miscarriage (15).
Therefore, and because of the high population frequency
of MBL deficiency, this condition could play an important
role in public health. However, the significance of MBL
deficiency in the adult general population remains rela-
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tively unknown because previous studies were mainly
based on hospital cases or children (5, 9–25).
We tested the hypothesis that MBL deficiency homozy-
gotes and heterozygotes compared with noncarriers are at
increased risk of morbidity and mortality from infectious
and other common diseases in the adult general population.
For this purpose, we screened 9,245 individuals from the
adult Danish population for the 
 
B
 
, 
 
C
 
, and 
 
D
 
 MBL defi-
ciency alleles, and associated MBL genotype with risk of
infection, other common diseases, and death during me-
dian follow-up periods of 24, 24, and 8 yr, respectively.
 
Materials and Methods
 
All subjects who participated in the 1991–1994 examination of
the Copenhagen City Heart Study were included in this popula-
tion-based study (Fig. 1, top; reference 26). The participants aged
20 yr and above were selected randomly after age stratification
into 5-yr age groups from among residents of Copenhagen. Of
the 17,180 individuals invited, 10,135 participated, 9,259 gave
blood, and 9,245 were genotyped for the 
 
B
 
, 
 
C
 
, and 
 
D
 
 deficiency
alleles of the MBL gene. Details of study procedures (26–29) and
some characteristics of nonresponders (30, 31) are described else-
where. More than 99% were Caucasians of Danish descent. All
participants gave written informed consent, and the ethics com-
mittee for Copenhagen and Frederiksberg approved the study
(no. 100.2039/91).
Participants at the Copenhagen City Heart Study examination
filled out a self-administered questionnaire, which was validated
by the participant and an investigator on the day of attendance.
Participants reported on smoking habits (current smoker, ex-
smoker, or never smoker), weekly physical activity (
 
 
 
2 h light
activity, 2–4 h light activity, 
 
 
 
4 h light activity, or 2–4 h heavy
activity or 
 
 
 
4 h heavy activity), and on weekly alcohol con-
sumption. Recent respiratory infection was self-reported (cold,
bronchitis, or lung infection) 4 wk before the Copenhagen City
Heart Study examination. Blood pressure was measured by
trained technicians using a London School of Hygiene Sphygmo-
manometer on the left arm after 5 min rest with the subject in the
sitting position (32). Cholesterol was determined enzymatically
by conventional methods (CHOD-PAP; Boehringer). Body mass
index was weight divided by height squared. Spirometry-defined
chronic obstructive pulmonary disease was FEV
 
1 
 
  
 
80% of pre-
dicted and FEV
 
1
 
/FVC 
 
  
 
0.7, excluding self-reported asthma.
Based on the World Health Organization International Classi-
fication of Diseases 8th and 10th
 
 
 
Editions, additional information
on morbidity was drawn from the Danish National Hospital Dis-
charge Register (data from May 1, 1976 to December 31, 2000
was available), whereas data on mortality was drawn from the
Danish National Register of Causes of Death (data from April 1,
1992 to December 31, 1999 was available for cause-specific
deaths, whereas data for death only was available until December
31, 2001). Of the 1,726 deaths, which occurred in the population
sample from 1991 through 2001, 1,065 (62%) had not yet been as-
signed with a certain death cause in the Danish National Register
of Causes of Death. We grouped all diagnoses based on the Global
Burden of Disease classification system (1, 2, 33). This paper fo-
cuses on groups of disease with high morbidity and mortality in
developed countries. Subclassification of the disease groups was
performed for endpoints particularly relevant for MBL deficiency.
During 1991 through 1993, we also recruited 947 patients
with ischemic heart disease (IHD) referred for coronary angiogra-
phy at Copenhagen University Hospital. Experienced cardiolo-
gists diagnosed IHD on the basis of characteristic symptoms of
stable angina pectoris plus at least one of the following: severe
stenosis on coronary angiography, myocardial infarction, or a
positive result on exercise electrocardiography. We further iden-
tified 701 patients with ischemic cerebrovascular disease (ICVD)
referred to Copenhagen University Hospital for outpatient ultra-
sonography of the carotid artery during 1994 through 2001.
ICVD was diagnosed on the basis of ischemic stroke, transient
ischemic attack, or amaourosis fugax, together with carotid artery
stenosis 
 
 
 
50%. All patients had computed tomography scans per-
formed, and those with cerebral hemorrhage were excluded. All
947 and 701 patients with IHD and ICVD were genotyped. For
each of these prevalent cases with ICVD and IHD, two control
subjects of the same gender, age (within 1 yr), and smoking status
(current smoker, ex-smoker, or never smoker) were randomly
selected among Copenhagen City Heart Study participants with-
Figure 1. Study design. 
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out ICVD and IHD using a computer matching program for
SPSS. For IHD and ICVD patients, 1,734 and 1,112 controls ful-
filled all three matching criteria, respectively (Fig. 1, bottom).
We identified the 
 
B
 
 (Gly54Asp), 
 
C
 
 (Gly57Glu), and 
 
D
 
(Arg52Cys) deficiency alleles of the MBL gene by RFLP-PCR
using the primers 5
 
 
 
-CATCAACGGCTTCCCAGGCAAAG-
ACGCG-3
 
  
 
(sense) and 5
 
 
 
-AGGATCCAGGCAGTTTCCT-
CTGGAAGG-3
 
  
 
(antisense; mismatches are underlined; refer-
ence 34). The presence of the B and D polymorphisms destroy a
BanI and HhaI site, respectively, whereas the presence of the C
polymorphism creates an MboII site. After restriction enzyme di-
gestion with BanI, HhaI, and MboII, fragments of 90 plus 35
(normal allele) or 125 bp (B allele), and fragments of 97 plus 28
bp (normal allele), 125 bp (D allele), or 69 plus 28 plus 28 bp (C
allele), were separated on two 4% agarose gels. Homozygotes and
compound heterozygotes were reanalyzed to confirm the diagno-
sis. Less severe promoter polymorphisms (6, 7) were not detected
using this assay.
Statistical analysis was performed with SPSS. P 
 
  
 
0.05 on
a two-sided test was considered significant. Pearson’s 
 
χ
 
2
 
-test,
Kruskal Wallis test, or ANOVA were used for univariate analyses.
Because deficiency 
 
B
 
,
 
 C
 
, and 
 
D
 
 alleles reduce plasma wild-type
MBL at about similar magnitudes in caucasian Danish adults (34),
our initial analyses were performed for the three alleles combined
as 
 
O
 
 alleles versus the 
 
A
 
 allele. However, we also looked at het-
erozygotes, compound heterozygotes, and homozygotes for each
of the 
 
B
 
,
 
 C
 
, and 
 
D
 
 alleles separately versus the 
 
A
 
 allele. As in pre-
vious studies, because genotype was already present at birth and
preceded the outcomes studied, we evaluated morbidity and
mortality incidences (Fig. 1, top) between genotypes using the
 
Table I.
 
Baseline Characteristics of Subjects Sampled from the General Population by MBL Deficiency Genotype
 
Noncarriers Heterozygotes Homozygotes P-value
 
a
 
Women/Men 2,962/2,398 1,880/1,502 275/228 0.91
Age, yr 57 
 
  
 
0.2 58 
 
  
 
0.3 58 
 
  
 
0.7 0.41
Current smokers (%) 2,621 (49) 1,624 (48) 246 (49) 0.82
Systolic blood pressure, mmHg 138 
 
  
 
0.3 139 
 
  
 
0.4 140 
 
  
 
1.0 0.21
Alcohol consumption, g/wk 114 
 
  
 
2.1 113 
 
  
 
2.6 109 
 
  
 
6.7 0.61
Plasma cholesterol, mmol/L 6.1 
 
  
 
0.02 6.2 
 
  
 
0.02 6.2 
 
  
 
0.06 0.13
Body mass index, kg/m
 
2
 
26 
 
  
 
0.2 26 
 
  
 
0.1 26 
 
  
 
0.1 0.59
Physical inactivity
 
b 
 
(%) 664 (13) 390 (12) 60 (12) 0.36
Values are number of individuals (%) or mean 
 
  
 
SEM.
 
a
 
P-values by Pearson’s 
 
χ
 
2
 
-test, Kruskal Wallis test, or analysis of variance. To approach normal distribution, body mass index was logarithmically
transformed before statistical analysis.
 
b
 
Physical inactivity was 
 
 
 
2 h of light physical activity per week.
 
Table II.
 
Morbidity Leading to Hospitalization According to MBL Deficiency Genotype during 24 yr Follow-up
 
Noncarriers Heterozygotes Homozygotes
Incidence
N/10,000
person 
 
  
 
yr RR
 
a
 
Incidence
N/10,000
person 
 
  
 
yr P-value
 
b
 
RR
 
a
 
(95% CI)
Incidence
N/10,000
person 
 
  
 
yr P-value
 
b
 
RR
 
a
 
(95% CI)
Any hospitalization 644 1.0 631 0.39 0.98 (0.93–1.0) 658 0.53 1.1 (0.96–1.2)
Infectious and parasitic diseases 55 1.0 57 0.58 1.1 (0.93–1.2) 50 0.48 0.91 (0.69–1.2)
Respiratory infections 42 1.0 37 0.09 0.88 (0.76–1.0) 40 0.75 0.96 (0.71–1.3)
Respiratory disorders 51 1.0 49 0.53 0.99 (0.87–1.1) 61 0.13 1.2 (0.97–1.6)
Cardiovascular disorders 136 1.0 132 0.38 0.95 (0.87–1.0) 162 0.02 1.2 (1.0–1.4)
Malignant neoplasms 61 1.0 62 0.77 1.0 (0.90–1.1) 65 0.64 1.0 (0.81–1.3)
Digestive disorders 118 1.0 112 0.20 0.95 (0.87–1.0) 135 0.10 1.2 (0.98–1.4)
Musculoskeletal disorders 140 1.0 135 0.28 0.96 (0.89–1.0) 140 0.96 1.0 (0.88–1.2)
Neuropsychiatric disorders 57 1.0 57 0.85 0.97 (0.89–1.1) 53 0.61 0.93 (0.71–1.2)
 
a
 
Relative risks (RR) were adjusted for gender, age, smoking habits, systolic blood pressure, alcohol, cholesterol, body mass index, and physical
inactivity.
 
b
 
P-values by log-rank test. Infectious and parasitic diseases: 001–136, 320, 323, 612–614, 620, 622, A00–B99, G00, G03–G04, N70–N73; respira-
tory infections: 460–486, 381–382, J00–J06, J10–J18, J20–J22, H65–H66; respiratory disorders: 490–519, J30–J98; cardiovascular disorders: 390–
458, I00–I99; malignant neoplasms: 140–209, C00–C97; digestive disorders: 530–577, K20–K92; musculoskeletal disorders: 710–738, M00–M99;
neuropsychiatric disorders: 290–315, 321–322, 324–358, F01–F99, G06–G98. 
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log-rank test (27–29). Cox regression analysis with forced entry
examined time to disease or death by using hazard ratios (relative
risks) and 95% confidence intervals (CIs). The model adjusted
for gender, age (deciles), smoking habits (current smoker, ex-
smoker, and never smoker), systolic blood pressure (deciles), al-
cohol consumption (nonusers and deciles), plasma cholesterol
(deciles), body mass index (deciles), and physical activity (
 
 
 
2 h
light activity weekly, 2–4 h light activity, 
 
 
 
4 h light activity, or
2–4 h heavy activity or 
 
 
 
4 h heavy activity weekly). Unadjusted
conditional logistic regression estimated odds ratios in matched
case control studies 1 and 2 (Fig. 1, bottom).
 
Role of the Funding Source.
 
The sponsors of the study are pub-
lic or nonprofit organizations and support science in general.
They had no role in gathering, analyzing, or interpreting the
data and could neither approve nor disapprove the submitted
manuscript.
 
Results
 
MBL genotype frequencies in this sample from the
Danish general population were 58% for 
 
A/A
 
 noncarri-
ers, 37% for 
 
A/O
 
 heterozygotes, and 5% for 
 
O/O
 
 defi-
ciency homozygotes. Frequencies for the 
 
B
 
,
 
 C
 
, and 
 
D
 
alleles were 0.145, 0.017, and 0.076, respectively. Ge-
notype frequencies did not differ from those predicted
by the Hardy-Weinberg equilibrium (
 
 
 
2
 
-test for 
 
B
 
 allele:
P 
 
  
 
0.75; 
 
C
 
 allele: P 
 
  
 
0.29; 
 
D
 
 allele: P 
 
  0.87). Distri-
bution of baseline characteristics in this population did
not differ between individuals with the three different
genotypes (Table I).
Morbidity. Incidence of any hospitalization per 10,000
person   yr was 644 in noncarriers compared with 631 in
heterozygotes (log-rank: P   0.39) and 658 in deficiency
homozygotes (P   0.53; Table II). After adjustment for
gender, age, smoking habits, systolic blood pressure, al-
cohol consumption, cholesterol level, body mass index,
and physical activity, the relative risks for any hospital-
ization were not significantly different from 1.0 in het-
erozygotes or deficiency homozygotes compared with
noncarriers.
After stratification by major causes of morbidity (1), in-
cidence of hospitalization from cardiovascular disorders
per 10,000 person   yr was 136 in noncarriers compared
with 132 in heterozygotes (P   0.38) and 162 in defi-
ciency homozygotes (P   0.02; Table II). Relative risks
Table III. Morbidity Leading to Hospitalization According to MBL Deficiency Genotype during 24 yr Follow-up
Noncarriers Heterozygotes Homozygotes
Incidence
N/10,000
person   yr RRa
Incidence
N/10,000
person   yr P-valueb
RRa
(95% CI)
Incidence
N/10,000
person   yr P-valueb
RRa
(95% CI)
Infectious diseases
Meningitis 0.91 1.0 1.1 0.69 0.99 (0.39–2.5) 0 — —
HIV/AIDS 0.68 1.0 0.60 0.82 0.75 (0.23–2.5) 0 — —
Tuberculosis 16 1.0 18 0.45 1.1 (0.88–1.4) 20 0.37 1.2 (0.80–1.9)
Pneumonia 29 1.0 25 0.18 0.89 (0.75–1.1) 32 0.47 1.1 (0.82–1.6)
Skin infection 9.9 1.0 9.7 0.90 1.0 (0.77–1.4) 12 0.41 1.2 (0.78–2.3)
Hepatitis 1.7 1.0 1.4 0.68 0.86 (0.42–1.7) 0.81 0.47 0.49 (0.07–3.7)
Diarrhoeal diseases 7.9 1.0 8.3 0.74 1.1 (0.81–1.5) 9.8 0.49 1.2 (0.68–2.3)
Cystitis 16 1.0 13 0.14 0.85 (0.67–1.1) 9.8 0.10 0.57 (0.32–1.0)
Pyelonephritis 3.6 1.0 3.9 0.74 1.1 (0.67–1.7) 5.7 0.24 1.7 (0.78–3.9)
Respiratory disorders
COPD 21 1.0 22 0.85 1.1 (0.87–1.3) 29 0.10 1.4 (0.97–2.0)
Asthma 8.9 1.0 8.2 0.59 0.89 (0.75–1.1) 8.1 0.77 1.1 (0.82–1.6)
Cardiovascular disorders
IHD 43 1.0 46 0.30 1.1 (0.94–1.2) 53 0.09 1.2 (0.92–1.6)
ICVD 21 1.0 20 0.65 0.97 (0.80–1.2) 28 0.10 1.2 (0.84–1.7)
Maternal conditions
Miscarriage 7.2 1.0 5.7 0.19 0.89 (0.62–1.3) 11 0.10 1.7 (0.96–3.1)
aRelative risks (RR) were adjusted for age, gender, smoking habits, systolic blood pressure, alcohol, cholesterol, body mass index, and physical
inactivity.
bP-values by log-rank test. Meningitis: 320, G00-G03; HIV/AIDS: 137, B20–B24; tuberculosis: 010–019, A15–A19, B90; pneumonia: 480–486,
J12–J18; skin infection: 680–686, L00–L08; hepatitis: 070, B15–B19; diarrhoeal diseases: 000–001,004–006, 008–009, A00–A01, A03–A04, A06–
A09; cystitis: 595, N30; pyelonephritis: 590, N10–N12; chronic obstructive pulmonary disease (COPD): 490–492, J41–J44; asthma: 493, J45–J46;
IHD: 410–414, I20–I25; ICVD: 430–438, I60–I69; miscarriage: 643, O03.Dahl et al. 1395
for cardiovascular disorders after adjustment for potential
confounders in heterozygotes and homozygotes com-
pared with noncarriers were 0.95 (95% CI: 0.87–1.0) and
1.2 (1.0–1.4), respectively. This finding was retested in
case control studies matched for gender, age, and smok-
ing habits. Odds ratios for ICVD, IHD, or either of these
diseases in deficiency homozygotes versus noncarriers
were 0.82 (0.53–1.3), 1.1 (0.76–1.5), and 1.1 (0.81–1.4),
respectively (not depicted). Incidence of hospitalization
from infection or other common diseases did not differ
between MBL genotypes (Table II).
After further stratification by specific hospitalization
cause, there were trends toward decreased incidence of
cystitis and increased incidence of chronic obstructive
pulmonary disease, IHD, ICVD, and miscarriage in MBL
deficiency homozygotes versus noncarriers (Table III).
However, there were no significant changes in risk.
Cross-sectionally, prevalence of recent respiratory in-
fection was 26% in noncarriers compared with 25% in
heterozygotes ( 2: P   0.72) and 28% in deficiency
homozygotes (P    0.21; not depicted). Prevalence of
spirometry-defined chronic obstructive pulmonary dis-
ease was 8.5% in noncarriers compared with 9.4% in het-
erozygotes (P   0.19) and 11% in homozygotes (P  
0.14; not depicted).
When B, C, and D deficiency alleles were looked at
separately versus noncarrier A alleles, none of the het-
erozygotes, compound heterozygotes, or homozygotes
were associated with incidence of any hospitalization
(Table IV). Compared with A/A noncarriers, A/D het-
erozygotes were associated with reduced risk of respira-
tory infection, A/C heterozygotes with reduced risk of
cardiovascular disorders, B/D compound heterozygotes
with increased risk of respiratory and digestive disorders,
whereas  D/D homozygotes were associated with in-
creased risk of digestive disorders. If correction for multi-
ple comparison is performed, all of these five significant
associations become nonsignificant. Therefore, and be-
cause none of the significant findings are biologically
plausible, these findings are likely due to chance alone
rather than representing real phenomena. The remaining
65 calculated relative risks were not significant.
Mortality. Incidence of death from any cause per
10,000 person   yr was 235 in noncarriers compared with
244 in heterozygotes (log-rank: P   0.44) and 274 in de-
ficiency homozygotes (P   0.12; Table V). After adjust-
ment for gender, age, smoking habits, systolic blood pres-
sure, alcohol consumption, cholesterol level, body mass
index, and physical activity, relative risks for death were
not significantly different from 1.0 in heterozygotes or
homozygotes compared with noncarriers.
After stratification by major causes of death (2), mor-
tality from cardiovascular disorders per 10,000 person   yr
was 41 in noncarriers compared with 31 in heterozygotes
(P   0.04) and 49 in deficiency homozygotes (P   0.44;
Table V). After adjustment for potential confounders, rel-
ative risks for death from cardiovascular disorders in het-
erozygotes and homozygotes compared with noncarriers
were 0.73 (95% CI: 0.55–0.95) and 1.1 (0.70–1.8), re-
spectively. Incidence of death from infection or other
common diseases did not differ between MBL genotypes.
When B, C, and D deficiency alleles were looked at
separately versus noncarrier A alleles, B/B homozygotes
were associated with increased incidence of death from
any cause (Table VI). None of the heterozygotes, com-
pound heterozygotes, or other homozygotes were associ-
ated with incidence of death from any cause. Compared
with A/A noncarriers, A/B heterozygotes were associ-
ated with reduced risk of death from cardiovascular disor-
ders. If correction for multiple comparison is performed,
both significant associations become nonsignificant. There-
fore, these findings are likely due to chance alone rather
than representing real phenomena. The remaining 41 cal-
culated relative risks were not significant.
Table IV. Morbidity Leading to Hospitalization According to MBL Deficiency Genotype during 24 yr Follow-up
Heterozygotes
Compound heterozygotes
or homozygotes
A/B A/D A/C B/B B/D D/D B/C D/Ca
Any hospitalization 1.0 (0.95–1.1) 0.93 (0.86–1.0) 0.98 (0.85–1.1) 1.0 (0.88–1.2) 1.1 (0.97–1.3) 1.1 (0.81–1.5) 1.0 (0.73–1.4) 0.81 (0.52–1.3)
Infectious and parasitic diseases 1.1 (0.94–1.3) 0.98 (0.81–1.2) 1.1 (0.81–1.6) 0.74 (0.46–1.2) 1.1 (0.72–1.6) 1.2 (0.60–2.4) 0.90 (0.37–2.2) 0.28 (0.04–2.0)
Respiratory infections 0.93 (0.78–1.1) 0.74 (0.58–0.94)b 1.0 (0.67–1.5) 0.94 (0.59–1.5) 1.2 (0.80–1.9) 0.43 (0.11–1.7) 0.67 (0.21–2.1) 0.80 (0.20–3.2)
Respiratory disorders 1.1 (0.93–1.2) 0.89 (0.73–1.1) 0.77 (0.51–1.2) 1.2 (0.82–1.8) 1.7 (1.2–2.4)b 0.67 (0.25–1.8) 0.96 (0.40–2.3) —
Cardiovascular disorders 0.96 (0.87–1.1) 0.98 (0.87–1.1) 0.77 (0.60–0.99)b 1.3 (0.97–1.6) 1.2 (0.93–1.5) 1.4 (0.91–2.3) 1.3 (0.78–2.1) 0.44 (0.16–1.2)
Malignant neoplasms 1.0 (0.90–1.2) 0.94 (0.78–1.1) 1.2 (0.88–1.6) 1.1 (0.78–1.6) 0.93 (0.63–1.4) 0.82 (0.37–1.8) 1.4 (0.73–2.7) 0.79 (0.25–2.5)
Digestive disorders 0.96 (0.87–1.1) 0.95 (0.83–1.1) 0.84 (0.64–1.1) 1.1 (0.80–1.4) 1.4 (1.1–1.8)b 1.6 (1.0–2.5)b 0.98 (0.54–1.8) 0.26 (0.07–1.1)
Musculoskeletal disorders 0.95 (0.86–1.0) 0.96 (0.85–1.1) 1.0 (0.83–1.3) 0.96 (0.73–1.3) 1.1 (0.88–1.5) 0.95 (0.57–1.6) 1.0 (0.59–1.8) 1.1 (0.58–2.2)
Neuropsychiatric disorders 0.96 (0.83–1.1) 0.99 (0.82–1.2) 0.93 (0.65–1.3) 0.94 (0.61–1.4) 1.2 (0.84–1.7) 0.43 (0.14–1.3) 0.86 (0.35–2.1) —
Values are relative risks (95% CI). Relative risks were adjusted for gender, age, smoking habits, systolic blood pressure, alcohol, cholesterol, body mass index, and physical inactivity. 
The A/A genotype was used as reference group.
aThe D/C genotype also included each of the following: C/C, B/B/D, B/B/C, and B/D/D.
bP   0.05 by Wald statistic. Infectious and parasitic diseases: 001–136, 320, 323, 612–614, 620, 622, A00–B99, G00, G03–G04, N70–N73; respiratory infections: 460–486, 381–
382, J00–J06, J10–J18, J20–J22, H65–H66; respiratory disorders: 490–519, J30–J98; cardiovascular disorders: 390–458, I00–I99; malignant neoplasms: 140–209, C00–C97; digestive
disorders: 530–577, K20–K92; musculoskeletal disorders: 710–738, M00–M99; neuropsychiatric disorders: 290–315, 321–322, 324–358, F01–F99, G06–G98.Morbidity and Mortality in Mannose-binding Lectin Deficiency 1396
Discussion
In this large study in an ethnically homogenous Cauca-
sian population, there was no evidence for differences in
infectious disease or mortality in MBL-deficient individuals
versus controls. Our results suggest that MBL deficiency is
not a major risk factor for morbidity or death in the adult
Caucasian population. These observations were indepen-
dent of major risk factors for morbidity and mortality (35)
such as gender, age, smoking, blood pressure, alcohol con-
sumption, cholesterol level, body mass index, and physical
inactivity.
Because  5% of Caucasians are MBL deficient, it is
indeed important that these individuals are relatively unaf-
fected by the deficiency. MBL replacement therapy is cur-
rently being evaluated (36–39). However, because MBL-
deficient individuals do not differ in morbidity or mortality
from noncarriers in this study, MBL reconstitution therapy
does not appear to be of relevance for the average Cauca-
sian MBL-deficient adult. Certainly, MBL replacement
therapy might be warranted in the future, if randomized
clinical trials can demonstrate improved clinical health status
in certain patient subgroups with MBL deficiency. Today,
however, diagnosing MBL deficiency among adults should
not alter management because predicted long-term morbid-
ity and mortality appear unaffected in these individuals.
Even though it is generally accepted that MBL is a central
factor in the innate immune system (5), MBL deficiency did
not increase risk for infection, other serious common dis-
eases, or death in this study. This indicates that other im-
mune systems, e.g., ficolins (5, 40), are able to take over
MBL function in most adults with MBL deficiency. In con-
cordance, MBL deficiency may only come into play when
other parts of the immune system are compromised, e.g., by
chemotherapy as shown in some (24, 41) but not all previ-
ous studies (42). MBL deficiency has been associated with
increased risk for severe and recurrent infections, but almost
solely in hospital-based studies (8). As opposed to this, our
results suggest that most adults with MBL deficiency in the
general population are asymptomatic. Thus, it appears that
MBL deficiency may only increase risk of infection in cer-
tain contexts or subgroups of patients, or when additional
impairments of the immune system are present (5).
Previous studies have shown an association between
MBL deficiency and accelerated progression of atheroscle-
rosis (9, 10, 43). This may lead to a higher incidence of car-
diovascular disease as observed in this study. This finding,
however, could not be confirmed in the matched case con-
trol studies in our study. Also, the number of deaths from
cardiovascular disorders was not increased by MBL defi-
ciency. Because of this, and because the risk estimate of 1.2
for cardiovascular disease was relatively small, we believe
that MBL deficiency is of no greater clinical importance in
cardiovascular disease. It cannot be ruled out, however,
that MBL deficiency in certain contexts (44) or subgroups
of patients may increase the risk of cardiovascular disease
significantly.
A population-based study of 252 children found that
MBL deficiency was associated with a twofold risk for acute
respiratory tract infection (17). In our study during adult-
hood, MBL deficiency did not increase risk of respiratory
infection outcomes on a population basis. Thus, it is possi-
Table V. Mortality According to MBL Deficiency Genotype during 8 yr Follow-up
Noncarriers Heterozygotes Homozygotes
Incidence
N/10,000
person   yr RRa
Incidence
N/10,000
person   yr P-valueb RRa (95% CI)
Incidence
N/10,000
person   yr P-valueb RRa (95% CI)
Death from any cause 235 1.0 244 0.44 1.0 (0.95–1.2) 274 0.12 1.1 (0.87–1.3)
Infectious and parasitic diseases 1.9 1.0 2.7 0.53 1.5 (0.52–4.2) 2.6 0.78 1.4 (0.17–13)
Respiratory infections 4.3 1.0 2.7 0.40 0.66 (0.28–1.6) 2.6 0.61 0.44 (0.05–3.6)
Respiratory disorders 14 1.0 10 0.14 0.73 (0.45–1.2) 18 0.56 1.2 (0.54–2.7)
Cardiovascular disorders 41 1.0 31 0.04 0.73 (0.55–0.95) 49 0.44 1.1 (0.70–1.8)
Malignant neoplasms 58 1.0 63 0.45 1.1 (0.90–1.3) 78 0.13 1.3 (0.87–1.9)
Digestive disorders 7.0 1.0 5.3 0.41 0.82 (0.42–1.6) 5.2 0.69 0.66 (0.15–2.8)
Musculoskeletal disorders 1.4 1.0 0 — — 0 — —
Neuropsychiatric disorders 3.4 1.0 3.4 0.96 1.4 (0.56–3.3) 0 — —
aRelative risks (RR) were adjusted for age, gender, smoking habits, systolic blood pressure, alcohol, cholesterol, body mass index, and physical
inactivity.
bP-values by log-rank test. Infectious and parasitic diseases: 001–136, 320, 323, 612–614, 620, 622, A00–B99, G00, G03–G04, N70–N73; respira-
tory infections: 460–486, 381–382, J00–J22, H65–H66; respiratory disorders: 490–519, J30–J99; cardiovascular disorders: 390–458, I00–I99; malig-
nant neoplasms: 140–209, C00–C97; digestive disorders: 530–577, K20–K99; musculoskeletal disorders: 710–738, M00–M99; neuropsychiatric dis-
orders: 290–315, 321–322, 324–358, F01–F99, G06–G98.Dahl et al. 1397
ble that MBL deficiency could play a role in pulmonary
host defense in children during the vulnerable period when
the adaptive immune system is immature (17), while not
having an effect in adults. It is also possible that risk of respi-
ratory infection is increased by MBL deficiency in children
of Inuit origin only (17), whereas risk is unaffected in chil-
dren (45) and adults in Caucasian populations.
Normal levels of MBL or wild-type genotype have also
been associated with higher incidence of disease by myco-
bacteria, indicating an advantage of the host in situations
where opsonophagocytosis might be detrimental (46, 47).
We were not able to support these previous observations.
However, in contrast to this study, the former studies used
different study designs or were performed in populations
where incidence for mycobacteria-associated disease is high.
Participants were genotyped only if they attended the
1991–1994 examination of the Copenhagen City Heart
Study. A selection bias may have occurred if death or mor-
bidity prevented certain individuals from being genotyped.
However, there are several arguments against such bias: (a)
the observed MBL genotype distribution did not differ
from that predicted by the Hardy-Weinberg equilibrium,
(b) MBL genotype distribution observed in the Copen-
hagen City Heart Study was similar to that observed in
other Caucasian populations (5), and (c) limiting the analy-
ses to a follow-up period after the 1991–1994 examination
yielded results similar to those presented. It should be
noted that if one insists on only looking at results after cor-
rection for multiple comparisons, MBL genotype was not
significantly associated with cardiovascular disease. As we
studied a sample of the caucasian Danish general popula-
tion, generalizability of our data to other races and to less
affluent parts of the world may potentially be constrained.
Bias caused by investigators’ knowledge of disease or risk
factor status seems unlikely because we selected from a
general population and genotyped our sample without
knowledge of disease status. Misclassification of genotypes
seems unlikely because the diagnosis of the B and D alleles
included a control site for restriction enzyme digestion, and
because all subjects with the MBL deficiency genotype
were reanalyzed to confirm the diagnosis.
In conclusion, we found no evidence for differences in
infectious disease or mortality in MBL-deficient individuals
versus controls. Our results suggest that MBL deficiency is
not a major risk factor for infection, other serious common
diseases, or death in the adult Caucasian population. These
are important findings because MBL replacement therapy is
currently under evaluation (36–39).
We thank Vibeke Wohlgehagen, Hanne Damm, and Birgit Hertz
for expert technical assistance, and Henrik Scharling, The Copen-
hagen City Heart Study, for statistical support.
This study is supported by the Danish Heart Foundation and the
Danish Lung Association. 
Submitted: 20 January 2004
Accepted: 7 April 2004
References
1. Murray, C.J.L., and A.D. Lopez. 1997. Global mortality, dis-
ability, and the contribution of risk factors: global burden of
disease study. Lancet. 349:1436–1442.
2. Murray, C.J.L., and A.D. Lopez. 1997. Mortality by cause for
eight regions of the world: global burden of disease study.
Lancet. 349:1269–1276.
3. Super, M., S. Thiel, J. Lu, R.J. Levinsky, and M.W. Turner.
1989. Association of low levels of mannan-binding protein
with a common defect of opsonisation. Lancet. 2:1236–1239.
4. Neth, O., D.L. Jack, A.W. Dodds, H. Holzel, N.J. Klein,
and M.W. Turner. 2000. Mannose-binding lectin binds to a
range of clinically relevant microorganisms and promotes
complement deposition. Infect. Immun. 68:688–693.
5. Holmskov, U., S. Thiel, and J.C. Jensenius. 2002. Collectins
and ficolins: humoral lectins of the innate immune defense.
Table VI. Mortality According to MBL Deficiency Genotype during 8 yr Follow-up
Heterozygotes
Compound heterozygotes
or homozygotes
A/B A/D A/C B/B B/D D/D B/C D/Ca
Death from any cause 1.1 (0.93–1.2) 1.0 (0.88–1.2) 1.1 (0.83–1.5) 1.4 (1.0–1.9)b 0.96 (0.69–1.3) 0.61 (0.27–1.4) 0.98 (0.51–1.9) 0.72 (0.29–1.7)
Infectious and parasitic diseases 2.4 (0.85–7.0) — — 3.2 (0.34–31) ————
Respiratory infections 0.56 (0.19–1.7) 0.73 (0.20–2.7) 1.1 (0.14–8.8) — 0.93 (0.09–9.2) — — —
Respiratory disorders 0.67 (0.38–1.2) 0.74 (0.33–1.6) 1.2 (0.36–3.8) 2.2 (0.77–6.3) 1.0 (0.24–4.3) 2.3 (0.30–17) — —
Cardiovascular disorders 0.72 (0.52–0.99)b 0.76 (0.50–1.2) 0.65 (0.27–1.6) 1.7 (0.89–3.2) 0.77 (0.31–1.9) 1.2 (0.28–4.7) 0.60 (0.08–4.3) 0.95 (0.13–7.0)
Malignant neoplasms 1.1 (0.87–1.4) 1.2 (0.85–1.6) 0.90 (0.49–1.7) 1.4 (0.76–2.4) 1.2 (0.65–2.2) 0.89 (0.22–3.6) 1.9 (0.69–5.1) 0.84 (0.12–6.0)
Digestive disorders 1.0 (0.38–2.7) 0.95 (0.83–1.1) — 1.3 (0.17–9.5) 0.69 (0.09–6.5) — — —
Musculoskeletal disorders — — — — ————
Neuropsychiatric disorders 1.8 (0.69–4.8) 0.42 (0.05–3.3) 2.8 (0.34–23) — ————
Values are relative risks (95% CI). Relative risks were adjusted for gender, age, smoking habits, systolic blood pressure, alcohol, cholesterol, body mass index, and physical inactivity. 
The A/A genotype was used as a reference group.
aThe D/C genotype also included each of the following: C/C, B/B/D, B/B/C, B/D/D.
bP   0.05 by Wald statistics. Infectious and parasitic diseases: 001–136, 320, 323, 612–614, 620, 622, A00–B99, G00, G03–G04, N70–N73; respiratory infections: 460–486, 381–
382, J00–J06, J10–J18, J20–J22, H65–H66; respiratory disorders: 490–519, J30–J99; cardiovascular disorders: 390–458, I00–I99; malignant neoplasms: 140–209, C00–C97; digestive
disorders: 530–577, K20–K99; musculoskeletal disorders: 710–738, M00–M99; neuropsychiatric disorders: 290–315, 321–322, 324–358, F01–F99, G06–G98.Morbidity and Mortality in Mannose-binding Lectin Deficiency 1398
Annu. Rev. Immunol. 21:547–578.
6. Terai, I., K. Kobayashi, M. Matsushita, H. Miyakawa, N.
Mafune, and H. Kikuta. 2003. Relationship between gene
polymorphisms of mannose-binding lectin (MBL) and two
molecular forms of MBL. Eur. J. Immunol. 33:2755–2763.
7. Garred, P., F. Larsen, H.O. Madsen, and C. Koch. 2003.
Mannose-binding lectin deficiency–revisited. Mol. Immunol.
40:73–84.
8. Eisen, D.P., and R.M. Minchinton. 2003. Impact of man-
nose-binding lectin on susceptibility to infectious diseases.
Clin. Infect. Dis. 37:1496–1505.
9. Rugonfalvi-Kiss, S., V. Endrész, H.O. Madsen, K. Burián, J.
Duba, Z. Prohászka, I. Karádi, L. Romics, É. Gönczöl, G.
Füst, et al. 2002. Association of chlamydia pneumoniae with
coronary artery disease and its progression is dependent on
the modifying effect of mannose-binding lectin. Circulation.
106:1071–1076.
10. Hegele, R.A., M.R. Ban, C.M. Anderson, and J.D. Spence.
2000. Infection susceptibility alleles of mannose-binding lec-
tin are associated with increased carotid plaque area. J. Inves-
tig. Med. 48:198–202.
11. Yang, I.A., S.L. Seeney, J.M. Wolter, E.M. Anders, J.G. Mc-
Cormack, A.M. Tunnicliffe, G.C. Rabnott, J.G. Shaw, A.G.
Dent, S.T. Kim, et al. 2003. Mannose-binding lectin gene
polymorphism predicts hospital admissions for COPD infec-
tions. Genes Immun. 4:269–274.
12. Nagy, A., G.T. Kozma, M. Keszei, A. Treszl, A. Falus, and
C. Szalai. 2003. The development of asthma in children in-
fected with chlamydia pneumoniae is dependent on the
modyfying effect of mannose-binding lectin. J. Allergy Clin.
Immunol. 4:729–734.
13. Nakagawa, T., B. Ma, K. Uemura, S. Oka, N. Kawasaki, and
T. Kawasaki. 2003. Role of mannan-binding protein, MBL,
in innate immunity. Anticancer Res. 23:4467–4471.
14. Schmiegelow, K., P. Garred, B. Lausen, B. Andreassen, B.L.
Petersen, and H.O. Madsen. 2002. Increased frequency of
mannose-binding lectin insufficiency among children with
acute lymphoblastic leukemia. Blood. 100:3757–3760.
15. Christiansen, O.B., D.C. Kilpatrick, V. Souter, K. Varming,
S. Thiel, and J.C. Jensenius. 1999. Mannan-binding lectin
deficiency is associated with unexplained recurrent miscar-
riage. Scand. J. Immunol. 49:193–196.
16. Garred, P., J.J. Strøm, L. Quist, E. Taaning, and H.O. Mad-
sen. 2003. Association of mannose-binding lectin polymor-
phisms with sepsis and fatal outcome, in patients with sys-
temic inflammatory response syndrome. J. Infect. Dis. 188:
1394–1403.
17. Koch, A., M. Melbye, P. Sørensen, P. Homøe, H.O. Mad-
sen, K. Mølbak, C.H. Hansen, L.H. Andersen, G.W. Hahn,
and P. Garred. 2001. Acute respiratory tract infections and
mannose-binding lectin insufficiency during early childhood.
JAMA. 285:1316–1321.
18. Garred, P., H.O. Madsen, B. Hofmann, and A. Svejgaard.
1995. Increased frequency of homozygosity of abnormal
mannan-binding-protein alleles in patients with suspected
immunodeficiency. Lancet. 346:941–943.
19. Summerfield, J.A., M. Sumiya, M. Levin, and M.W. Turner.
1997. Association of mutations in mannose binding protein
gene with childhood infection in consecutive hospital series.
BMJ. 314:1229–1232.
20. Hibberd, M.L., M. Sumiya, J.A. Summerfield, R. Booy, and
M. Levin. 1999. Association of variants of the gene for man-
nose-binding lectin with susceptibility to meningococcal dis-
ease. Lancet. 353:1049–1053.
21. Garred, P., H.O. Madsen, U. Balslev, B. Hofmann, C. Pe-
dersen, J. Gerstoft, and A. Svejgaard. 1997. Susceptibility to
HIV infection and progression of AIDS in relation to variant
alleles of mannose-binding lectin. Lancet. 349:236–240.
22. Garred, P., T. Pressler, H.O. Madsen, B. Frederiksen, A.
Svejgaard, N. Høiby, M. Schwartz, and C. Koch. 1999. As-
sociation of mannose-binding lectin gene heterogeneity with
severity of lung disease and survival in cystic fibrosis. J. Clin.
Invest. 104:431–437.
23. Roy, S., K. Knox, S. Segal, D. Griffiths, C.E. Moore, K.I.
Welsh, A. Smarason, N.P. Day, W.L. McPheat, D.W.
Crook, et al. 2002. MBL genotype and risk of invasive pneu-
mococcal disease: a case-control study. Lancet. 359:1569–
1573.
24. Neth, O., I. Hann, M.W. Turner, and N.J. Klein. 2001. De-
ficiency of mannose-binding lectin and burden of infection
in children with malignancy: a prospective study. Lancet. 358:
614–618.
25. Yuen, M.-F., C.-S. Lau, Y.-L. Lau, W.-M. Wong, C.-C.
Cheng, and C.-L. Lai. 1999. Mannose-binding lectin gene
mutations are associated with progression of liver disease in
chronic hepatitis B infection. Hepatology. 29:1248–1251.
26. Schnohr, P., G. Jensen, P. Lange, H. Scharling, and M. App-
leyard. 2001. The Copenhagen City Heart Study–Øster-
broundersøgelsen. Tables with data from the third examina-
tion 1991–1994. Eur. Heart J. Suppl. 3:H1–H83.
27. Juul, K., A. Tybjærg-Hansen, R. Steffensen, S. Kofoed, G.
Jensen, and B.G. Nordestgaard. 2002. Factor V leiden: The
Copenhagen City Heart Study and 2 meta-analyses. Blood.
100:3–10.
28. Bojesen, S.E., A. Tybjærg-Hansen, and B.G. Nordestgaard.
2003. Integrin  3 Leu33Pro homozygosity and risk of cancer.
J. Natl. Cancer Inst. 95:1150–1157.
29. Dahl, M., A. Tybjærg-Hansen, P. Lange, J. Vestbo, and B.G.
Nordestgaard. 2002. Change in lung function and morbidity
from chronic obstructive pulmonary disease in  1-antitrypsin
MZ heterozygotes: a longitudinal study of the general popu-
lation. Ann. Intern. Med. 136:270–279.
30. Jensen, G. 1984. Epidemiology of chest pain and angina pec-
toris, with special reference to treatment needs. Acta Med.
Scand. Suppl. 682:1–120.
31. Dahl, M., B.G. Nordestgaard, P. Lange, J. Vestbo, and A.
Tybjærg-Hansen. 2001. Molecular diagnosis of intermediate
and severe  1-antitrypsin deficiency: MZ individuals with
chronic obstructive pulmonary disease may have lower lung
function than MM individuals. Clin. Chem. 47:56–62.
32. Dahl, M., A. Tybjærg-Hansen, H. Sillesen, G. Jensen, R.
Steffensen, and B.G. Nordestgaard. 2003. Blood pressure,
risk of ischemic cerebrovascular and ischemic heart disease,
and longevity in  1-antitrypsin deficiency. The Copenhagen
City Heart Study. Circulation. 107:747–752.
33. Mathers, C.D., C. Stein, D.M. Fat, C. Rao, M. Inoue, N.
Tomijima, C. Bernard, A.D. Lopez, and C.J.L. Murray. 2002.
Global burden of disease 2000. Version 2 methods and results.
Global Programme on Evidence for Health Policy Discussion Paper
no. 50. World Health Organisation, Geneva. pp.55–59.
34. Madsen, H.O., P. Garred, J.A.L. Kurtzhals, L.U. Lamm, L.P.
Ryder, S. Thiel, and A. Svejgaard. 1994. A new frequent al-
lele is the missing link in the structural polymorphism of the
human mannan-binding protein. Immunogenetics. 40:37–44.
35. Ezzati, M., A.D. Lopez, A. Rodgers, S.V. Hoorn, and C.J.
Murray. 2002. Selected major risk factors and global and re-Dahl et al. 1399
gional burden of disease. Lancet. 360:1347–1360.
36. Valdimarsson, H., M. Stefansson, T. Vikingsdottir, G.J. Ara-
son, C. Koch, S. Tiehl, and J.C. Jensenius. 1998. Reconstitu-
tion of opsonizing activity by infusion of mannan-binding
lectin (MBL) to MBL-deficient humans. Scand. J. Immunol.
48:116–123.
37. Valdimarsson, H., T. Vikingsdottir, P. Bang, S. Saevarsdottir,
J.E. Gudjonsson, O. Oskarsson, M. Christiansen, L. Blou, I.
Laursen, and C. Koch. 2004. Human plasma-derived man-
nose-binding lectin: a phase I safety and phamacokinetic
study. Scand. J. Immunol. 59:97–102.
38. Jensenius, J.C., P.H. Jensen, K. McGuire, J.L. Larsen, and S.
Thiel. 2003. Recombinant mannan-binding lectin (MBL) for
therapy. Biochem. Soc. Trans. 31:763–767.
39. Garred, P., T. Pressler, S. Lanng, H.O. Madsen, C. Moser, I.
Laursen, F. Balstrup, C. Koch, and C. Koch. 2002. Man-
nose-binding lectin (MBL) therapy in an MBL-deficient pa-
tient with severe cystic fibrosis lung disease. Pediatr. Pulmonol.
33:201–207.
40. Matsushita, M., M. Kuraya, N. Hamasaki, M. Tsujimura, H.
Shiraki, and T. Fujita. 2002. Activation of the lectin comple-
ment pathway by H-ficolin (Hakata Antigen). J. Immunol.
168:3502–3506.
41. Peterslund, N.A., C. Koch, J.C. Jensenius, and S. Thiel.
2001. Association between deficiency of mannose-binding
lectin and severe infections after chemotherapy. Lancet. 358:
637–638.
42. Kilpatrick, D.C., L.A. Mclintock, E.K. Allan, M. Copland,
T. Fujita, N.E. Jordanides, C. Koch, M. Matsushita, H.
Shiraki, K. Stewart, et al. 2003. No strong relationship be-
tween mannan binding lectin or plasma ficolins and chemo-
therapy-related infections. Clin. Exp. Immunol. 134:279–284.
43. Madsen, H.O., V. Videm, A. Svejgaard, J.L. Svennevig, and
P. Garred. 1998. Association of mannose-binding lectin defi-
ciency with severe atherosclerosis. Lancet. 352:959–960.
44. Best, L.G., M. Davidson, K.E. North, J.W. MacCluer, Y.
Zhang, E.T. Lee, B.V. Howard, S. DeCroo, and R.E. Ferrel.
2004. Prospective analysis of mannose-binding lectin geno-
types and coronary artery disease in American Indians. Circu-
lation. 109:471–475.
45. Nielsen, H.E., V. Siersma, S. Andersen, B. Gahrn-Hansen,
C.H. Mordhorst, B. Norgaard-Pedersen, B. Roder, T.L. So-
rensen, R. Temme, and B.F. Vestergaard. 2003. Respiratory
syncytial virus infection—risk factors for hospital admission: a
case-control study. Acta Paediatr. 92:1314–1321.
46. Hoal-Van Helden, E.G., J. Epstein, T.C. Victor, D. Hon,
L.A. Lewis, N. Beyers, D. Zurakowski, A.B. Ezekowitz, and
P.D. Van Helden. 1999. Mannose-binding protein B allele
confers protection against tuberculous meningitis. Pediatr.
Res. 45:459–464.
47. Søborg, C., H.O. Madsen, Å.B. Madsen, T. Lillebaek, A.
Kok-Jensen, and P. Garred. 2003. Mannose-binding lectin
polymorphisms in clinical tuberculosis. J. Infect. Dis. 188:
777–782.